Mycelx Technologies Corp. · LSE:MYX
Mycelx Technologies — Investor Presentation (February 2022)
22 slides from Mycelx Technologies's investor presentation, February 2022
Slide 1: MYCELX Investor Presentation
MYCELX INVESTOR PRESENTATION Reducing the Impact of Industry on the Environment February 2022
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by MYCELX Technologies Corporation (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been independently ver
Slide 3: Board of Directors & Management
BOARD OF DIRECTORS & MANAGEMENT Experienced leadership to unlock technology’s full potential TOM LAMB CONNIE MIXON HAL ALPER ANDRE SCHNABL Non-Exec Chief Executive President & Chief Senior Non-Exec Chairman Officer Science Officer Director Over 30 years of leadership Experienced strategic and Invent
Slide 4: Introduction
INTRODUCTION Accelerating a Sustainable Future • MYCELX is an environmental water technology company with patented, unique technology currently operating in the following primary markets: – PFAS remediation – MYCELX’s technology is able to remove these “forever chemicals” from water to non-detectabl
Slide 5: IP Secured & Targeted R&D Efforts
IP SECURED & TARGETED R&D EFFORTS 36 Global Patents • MYCELX’s IP is secured via 36 Global Patents New applications • We avoid operating in jurisdictions where IP infringement for MYCELX poses the greatest risk developed by our ongoing R&D • Active R&D efforts to solve customers’ ESG challenges effo
Slide 6: PFAS: Tackling the global crisis
PFAS: Tackling the global crisis
Slide 7: PFAS – A Global Environmental Crisis
PFAS – A GLOBAL ENVIRONMENTAL CRISIS Growing realization of the scale of the problem Persistent Bioaccumulative Mobile Hazardous ▪ “Forever Chemical” ▪ Accumulates in the ▪ Ubiquitous – quickly ▪ Toxic at <70ppt that does not body reaches groundwater (less than 4 drops naturally degrade and seawater
Slide 8: PFAS: MYCELX's Competitive Advantage
PFAS: MYCELX’S COMPETITIVE ADVANTAGE Broad Spectrum Removal, Efficient Footprint & Reduced Waste Comprehensive & Future Proof: PFAS Analyte Removal Comparison: • MYCELX is capable of removing a broader spectrum of PFAS analytes than conventional technology which focus on PFOS/PFOA • PFAS compounds n
Slide 9: PFAS – A Global Environmental Crisis
PFAS – A GLOBAL ENVIRONMENTAL CRISIS Growing realization of the scale of the problem There are ‘forever chemicals’ in beef now High levels of toxic chemicals found in Toxic 'forever chemicals' Cambridgeshire water supply found in British otters Potentially dangerous chemicals in ground water at Air
Slide 10: Latest PFAS Regulatory Updates in US
LATEST PFAS REGULATORY UPDATES IN US • EPA submitted a plan designating two legacy PFAS contaminants as “hazardous substances” - significant financial impact as EPA will be able to force clean up or reimbursement (Jan 2022) • EPA evaluation of the potential human health risks may drive remedial targ
Slide 11: Recent PFAS Trial
RECENT PFAS TRIAL Succeeded with 99.9% removal efficiency CUSTOMER: Department of Defence Environmental Contractor SITE: Upstate NY, Industrial site. Source of contamination from AFFF OBJECTIVE: Demonstrate ability of MYCELX to reduce PFAS contaminants and co-contaminants to non-detect levels RESULT
Slide 12: What's Next for PFAS?
WHAT’S NEXT FOR PFAS? • Broad marketing campaign and hire of experienced BD professionals to drive customer education and project wins • Advanced discussions with an environmental engineering prime contractor are underway for long-term engagement to demonstrate operational superiority by significant
Slide 13: Oil & Gas: Reducing the environmental impact of industry
OIL & GAS: Reducing the environmental impact of industry
Slide 14: Technology Overview
TECHNOLOGY OVERVIEW Technology – MYCELX’s MYCELX’s treatment media (polymer) is MYCELX’s treatment media is patented polymer infused into purpose built back-washable housed inside specially modified media or standard filters standard vessels Inlet Outlet of Coalescer Outlet of RE-GEN Filter replacem
Slide 15: Our Global Footprint
OUR GLOBAL FOOTPRINT Key clients include: Current Operations: MYCELX CONFIDENTIAL - © MYCELX 2022 15
Slide 16: Oil & Gas: Enhanced Oil Recovery
OIL & GAS: ENHANCED OIL RECOVERY Water Treatment is the key to unlocking EOR options for existing fields Reduce the need for new reservoir development • Optimise production from existing infrastructure • Proprietary equipment Retrofit Package enables drop-in of REGEN to replace 50-year-old Nutshell
Slide 17: Proposed Placing to Raise c$4m: Structure and Timetable
PROPOSED PLACING TO RAISE c$4m STRUCTURE AND TIMETABLE USES OF FUNDS CAPITAL USES FUNDS CAPITAL STRUCTURE STRUCTURE OF STRUCTURE CAPITAL USES OF FUNDS PFAS TECHNOLOGY COMMERCIALIZATION - $2.6 • Ordinary share in issue 19,443,750 million • Outstanding share Options 1,663,000 • Build equipment for tri
Slide 18: Conclusion
CONCLUSION Industry-leading technologies to facilitate a sustainable future • Novel opportunity in the US through technological superiority to be a product leader in solutions for the global PFAS crisis • Oil & Gas solutions are established and growing and our REGEN media effectively treats difficul
Slide 19: Appendix
APPENDIX MYCELX(?*
Slide 20: FY2021 in Review
FY2021 IN REVIEW Pursuing Growth • Middle East: – Significant new contract and 2 contract extensions – Two separate contract wins including REGEN media sale and paid REGEN trial • US PFAS Market: – Completed successful trial and fabrication of two systems • US Business Development: – Seasoned Busine
Slide 21: Financial Statements
FINANCIAL STATEMENTS Profit and Loss Six Months ended Six Months ended 30 June 2021 30 June 2020 Year Ended 31 (US$000): (unaudited) (unaudited) December 2020 Revenue 4,164 3,641 7,104 Cost of goods sold 2,266 1,993 5,512 Gross profit 1,898 1,648 1,592 Operating expenses: Research and development -
Slide 22: Financial Statements: Balance Sheet and Cash Flow
FINANCIAL STATEMENTS Condensed Balance Sheet As of 30 June As of 30 2021 June 2020 As of 31 Dec (US$000s) (unaudited) (unaudited) 2020 Intangibles 783 778 790 PP&E and Operating lease asset 3,835 8,111 7,238 Fixed Assets 4,618 8,889 8,028 Working Capital 4,473 5,389 3,788 Cash, cash equivalents and
MYCELX Technologies — Investor Presentation (February 2022) on 6ix